Ikena Oncology (NASDAQ: IKNA)
$1.28
(-1.2%)
-$0.02
Price as of July 17, 2025, 1:50 p.m. ET
Ikena Oncology Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ikena Oncology Company Info
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed, and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.